EVIDENCE FOR A DISSOCIATION IN THE CONTROL OF SPARTEINE, DEBRISOQUINE AND METOPROLOL METABOLISM IN NIGERIANS

被引：47

作者：

LENNARD, MS

IYUN, AO

JACKSON, PR

TUCKER, GT

WOODS, HF

机构：

[1] University Department of Medicine and Pharmacology, Royal Hallamshire Hospital, Sheffield

[2] Department of Medicine, University College Hospital, Ibadan

来源：

PHARMACOGENETICS | 1992年 / 2卷 / 02期

关键词：

D O I：

10.1097/00008571-199204000-00006

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The 0-8 hour urinary distributions of the metabolic ratios of sparteine (100 mg), debrisoquine (10 mg) and metoprolol (100 mg) were measured in 165 healthy, unrelated, black Nigerian medical students. There was a weak correlation (r(s) = 0.51, p < 0.001; n = 82) between the metoprolol/alpha-hydroxymetoprolol (M/HM) and the sparteine/total (2- + 5-) dehydrosparteine (S/DHS) ratios. No significant correlations were found between the debrisoquine/4-hydroxydebrisoquine (D/HD) and M/HM ratios (r(s) = 0.16, n = 33) and between the D/HD and S/DHS ratios (r(s) = 0.31, n = 38). Both visual inspection and kernel density analysis of the data suggested the presence of two phenotypic groups for sparteine oxidation, with 4% of the population studied being putative poor metabolizers. In contrast bimodality was not apparent in the distribution of the log10M/HM and log10D/HD ratios. These findings provide evidence for a dissociation in the control of metoprolol, sparteine and debrisoquine oxidation in Nigerians and highlight the difficulties in the interpretation of data from pharmacogenetic studies in different ethnic groups.

引用

页码：89 / 92

页数：4

共 23 条

[1]

Alvan G., Bechtel B., Iselius L., Gundert-Remy U., Hydroxylation polymorphisms of dcbrisoquine and mephenytoin in European populations, Eur J Clin Pharmacol, 39, pp. 533-537, (1990)

[2]

Daly A.K., Armstrong M., Monkman S.C., Idle M.E., Idle J.R., Genetic and metabolic criteria for the assignment of debrisoquine4-hvdroxylation (Cytochrome P4502D6) phenotypes, Pharmacogenetics, 1, pp. 35-41, (1991)

[3]

Eichelbaum M., Gross A.S., The genetic polymorphisms of debriso-quine sparteine metabolism-clinical aspects, Pharmacol Ther, 46, 3, pp. 77-394, (1990)

[4]

Gough A.C., Miles J.S., Spurr N.K., Moss J.K., Gaedigk A., Eichclbaum M., Wolf C.R., Identification of the primary gene defect at the cytochrome P450 CYP2I) locus, Satwe, 347, (1990)

[5]

Heim M., Meyer U.A., Denotvping of poor metabolisers of debriso-quine by allele-specilic PCR amplification, Lance, 529, 32, (1990)

[6]

Iyun A.O., Lennard M.S., Tucker G.T., Woods H.F., Woods HF Metoprolol and debrisoquine metabolism in Nigerians: Lack of evidence for polymorphic oxidation, Clin Pharmacol Ther, 40, pp. 387-594, (1986)

[7]

Jackson P.R., Tucker G.T., Woods H.F., Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism- hypothesis testing, Br J Clin Pharmacol, 28, pp. 655-662, (1989)

[8]

Johansson I., Yue Q.Y., Dahl M.-L., Heim M., Denetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine, Bur J Clin Pharmacol, 40, 553, (1990)

[9]

Lancaster D.R., Adio R.A., Tai K.K., Simooya O.O., Broadhead G.D., Tucker G.T., Lennard M.S., Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs, Phann Pharmacol, 42, pp. 267-271, (1990)

[10]

Lennard M.S., Silas J.H., Smith A.J., Tucker G.T., Determination of debrisoquine and its 4-hydroxymetaboIite in biological fluids by gas chromatography with tlame ionisation and nitrogen-selective detection, J Chromatogr, 133, pp. 161-166, (1977)

← 1 2 3 →